Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2180 - Pharmacogenomic predictors of cisplatin oto- and nephrotoxicity in head and neck cancer patients treated with chemoradiation


09 Oct 2016


Poster display


Eric Winquist


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


E. Winquist1, W.A. Teft2, A. Nichols3, C. Parker3, M. Trinnear1, P. Francis1, N. Bukhari1, J. Lukovic1, Y. Choi2, S. Kuruvilla1, S. Richter1, A. Hammond1, D. Macneil3, N. Read1, K. Fung3, V. Venkatesan1, S. Welch1, D. Palma1, J. Yoo3, R.B. Kim2

Author affiliations

  • 1 Department Of Oncology, University of Western Ontario, N6A 5W9 - London/CA
  • 2 Department Of Medicine, University of Western Ontario, N6A 5A5 - London/CA
  • 3 Department Of Otolaryngology-head&neck Surgery, University of Western Ontario, N6A 5W9 - London/CA


Abstract 2180


Cisplatin-based chemoradiotherapy (CRT) remains a standard treatment for patients (pts) with locally advanced head and neck squamous cell carcinomas (HNSCCs). However, use of cisplatin may cause oto- and nephrotoxicity which may compromise both treatment delivery and longterm quality of life. We hypothesized that polymorphisms (SNPs) in cisplatin methyltransferases (TPMT, COMT), acylphosphatases (ACYP2) and transporters (CTR1, OCT2, MATE1, ABCC2, ABCC3) could predict oto- and nephrotoxicity and investigated this in a prospective cohort study.


Consenting HNSCC pts with adequate baseline hearing and renal function treated with CRT were prospectively enrolled. Audiometric testing was done at baseline, and 3, 6, 12 & 18 months. Serum creatinine was assessed baseline & weekly during CRT. Ototoxicity was defined as ≥grade 2 audiometric change from baseline (CTCAE v4.02) present 12 months post-treatment. Nephrotoxicity was defined as ≥grade 2 acute kidney injury after initiation of cisplatin. Relationships between clinical variables, genotype and outcomes were assessed using Cox regression with interval censoring and reported as a hazard ratio (HR).


207 consecutive HNSCC pts have been enrolled. To date ≥grade 2 ototoxicity has developed in 64% and ≥grade 2 nephrotoxicity observed in 22% of 170 evaluable pts. In multivariate analyses TPMT and COMT SNP carriers were at increased risk of developing ototoxicity (HR 4.47 [95%CI 1.66-12.03, p 


Oto- and nephrotoxicity occur frequently in HNSCC pts treated with CRT. SNPs in both cisplatin metabolizing enzymes and transporters appear to predict vulnerability to these. We plan to assess the clinical utility of these SNPs for toxicity avoidance in a prospective clinical trial.

Clinical trial identification

Not applicable.

Legal entity responsible for the study

University of Western Ontario


Ontario Institute of Cancer Research, Cancer Care Ontario, London Regional Cancer Program, LRCP Medical Oncology Research Fund


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings